Novartis (NVS) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.
Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.
The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.
Novartis said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.
Price: 100.79, Change: -0.89, Percent Change: -0.88
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。